Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR PRESERVATIVE FREE vs AKTOB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
FDA-approved: Treatment of ocular inflammation and pain following cataract surgery and corneal refractive surgery.,Off-label: Relief of seasonal allergic conjunctivitis symptoms, management of cystoid macular edema, and treatment of postoperative inflammation in other ocular procedures.
Prevention of organ rejection in kidney, liver, and heart transplants,Rheumatoid arthritis,Psoriasis
1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.
Adults: 10 mg orally once daily.
Terminal elimination half-life is approximately 5-6 hours in adults, but can be prolonged in elderly patients (up to 8-9 hours) and in patients with renal impairment (up to 13-19 hours).
Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria).
Ketorolac undergoes hepatic metabolism via hydroxylation and conjugation (glucuronidation) to inactive metabolites. It is primarily metabolized by CYP2D6 and CYP3A4 isoenzymes, with renal excretion of metabolites and unchanged drug.
Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N.
Primarily renal excretion of metabolites and unchanged drug; approximately 80% of a dose is excreted in urine as ketorolac and its hydroxy metabolites, with about 6% excreted in feces.
Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites.
99% bound to plasma proteins, primarily albumin.
20-30% primarily to albumin.
0.15-0.25 L/kg after oral administration; for ophthalmic use, systemic absorption is minimal, so Vd is not clinically meaningful.
0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid.
Ophthalmic administration: Systemic bioavailability is approximately 0.5-1% after ocular instillation due to low corneal penetration and rapid clearance; oral bioavailability is 100%.
Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract).
No dosage adjustment required for renal impairment. Drug is minimally absorbed systemically.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min or dialysis: 2.5 mg once daily.
No dosage adjustment required for hepatic impairment. Drug is minimally absorbed systemically.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Children ≥3 years: 1 drop into affected eye(s) four times daily. Safety and efficacy in children <3 years not established.
Not established for children <18 years.
No specific dosage adjustment required. Use same dose as adults; monitor for tolerability.
No specific dose adjustment; monitor for hypotension and renal function.
NSAIDs may increase the risk of serious cardiovascular events (e.g., myocardial infarction, stroke) and gastrointestinal events (e.g., bleeding, ulceration, perforation). However, due to low systemic absorption with ophthalmic use, this boxed warning is less clinically relevant but still applies.
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
Use with caution in patients with compromised ocular surface, history of herpes simplex keratitis, bleeding tendencies, or those on anticoagulants. Prolonged use may delay wound healing. Monitor for signs of corneal epithelial breakdown or infection.
Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation).
Hypersensitivity to ketorolac or any component of the formulation; patients with active ocular infection or advanced dry eye; history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
No known food interactions. No dietary restrictions required.
No significant food interactions. Avoid alcohol while taking this medication.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to 1.5-3 times the human exposure. However, because NSAIDs can cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester, use is contraindicated after 30 weeks gestation. In first and second trimesters, use only if potential benefit justifies potential fetal risk.
First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios.
Ketorolac is excreted in human milk following oral administration. After a single intramuscular dose of 10 mg, the milk-to-plasma (M/P) ratio was 0.037. Low levels are expected in breastmilk; however, due to potential adverse effects of NSAIDs on neonates, caution is advised. Use is generally avoided in nursing mothers, especially with premature infants or those with thrombocytopenia or renal impairment.
Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk.
No specific pharmacokinetic studies in pregnancy. Dosing should be at the lowest effective dose for the shortest duration. Avoid use after 30 weeks gestation. No adjustment for first or second trimester unless renal function changes.
No standard dose adjustment; increased clearance in pregnancy may require higher doses; therapeutic drug monitoring advised.
ACULAR (ketorolac tromethamine ophthalmic solution) is an NSAID for ocular use. Preservative-free formulation is indicated for single-use to avoid corneal toxicity. Apply with caution in patients with bleeding disorders or those on anticoagulants due to risk of ocular bleeding. Prolonged use may delay corneal healing. Monitor for signs of keratitis or conjunctival hyperemia.
AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (Cr Cl <30 m L/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection.
Use exactly as prescribed; do not touch the dropper tip to any surface to avoid contamination.,Each single-use vial is for one dose only; discard after use to prevent infection.,Remove contact lenses before instillation and wait 10 minutes before reinserting.,Do not drive or operate machinery if vision is blurry after application.,Report eye pain, increased redness, or vision changes to your doctor immediately.
Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,Inform your doctor if you have kidney problems or are on dialysis.,This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR PRESERVATIVE FREE vs AKTOB, answered by our medical review team.
ACULAR PRESERVATIVE FREE is a NSAID Ophthalmic that works by Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. It produces anti-inflammatory and analgesic effects.. AKTOB is a Aminoglycoside Antibiotic (Ophthalmic) that works by Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR PRESERVATIVE FREE and AKTOB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR PRESERVATIVE FREE is: 1 drop into affected eye(s) four times daily (every 6 hours). Instill into conjunctival sac. Shake well before use.. The standard adult dose of AKTOB is: Adults: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR PRESERVATIVE FREE and AKTOB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR PRESERVATIVE FREE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, ketorolac tromethamine (active ingredient) was not teratogenic in rats or rabbits at doses up to. AKTOB is classified as Category C. First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.